CD8A and cancer: The study revealed that after immunotherapy, the use of PD-1 blockers before surgery not only improves the response of anti-tumor T cells, but also stimulates the peripheral blood's production of CD8+T cells with memory characteristics, and continuously terminates cancer cells through the T cells’ anti-tumor activity.